Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:EXOZ NASDAQ:MGNX NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.94+1.5%$1.20$0.82▼$4.08$251.82M0.263.67 million shs5.53 million shsEXOZeXoZymes$7.35+3.5%$9.83$7.08▼$18.40$62.33M2.664,475 shs1,644 shsMGNXMacroGenics$4.13+4.3%$3.68$1.18▼$4.64$262.52M1.181.07 million shs620,423 shsZNTLZentalis Pharmaceuticals$3.78+0.8%$4.01$1.13▼$6.95$269.10M1.971.76 million shs1.26 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-1.15%-12.78%-38.77%-74.03%EXOZeXoZymes0.00%-21.94%-27.32%-2.67%-44.57%MGNXMacroGenics0.00%+1.28%-6.82%+27.74%+160.53%ZNTLZentalis Pharmaceuticals0.00%+2.46%-7.41%+38.38%+179.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.94+1.5%$1.20$0.82▼$4.08$251.82M0.263.67 million shs5.53 million shsEXOZeXoZymes$7.35+3.5%$9.83$7.08▼$18.40$62.33M2.664,475 shs1,644 shsMGNXMacroGenics$4.13+4.3%$3.68$1.18▼$4.64$262.52M1.181.07 million shs620,423 shsZNTLZentalis Pharmaceuticals$3.78+0.8%$4.01$1.13▼$6.95$269.10M1.971.76 million shs1.26 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-1.15%-12.78%-38.77%-74.03%EXOZeXoZymes0.00%-21.94%-27.32%-2.67%-44.57%MGNXMacroGenics0.00%+1.28%-6.82%+27.74%+160.53%ZNTLZentalis Pharmaceuticals0.00%+2.46%-7.41%+38.38%+179.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67397.14% UpsideEXOZeXoZymes 1.00SellN/AN/AMGNXMacroGenics 2.29Hold$5.5033.17% UpsideZNTLZentalis Pharmaceuticals 2.14Hold$5.8354.32% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, MGNX, ZNTL, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026EXOZeXoZymes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/22/2026ZNTLZentalis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/8/2026MGNXMacroGenics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026MGNXMacroGenics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.004/10/2026MGNXMacroGenics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.00 ➝ $9.004/10/2026ZNTLZentalis Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.004/7/2026ZNTLZentalis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.07N/AN/A$0.12 per share7.82EXOZeXoZymes$70K890.40N/AN/A$0.40 per share18.38MGNXMacroGenics$157.08M1.67N/AN/A$0.88 per share4.69ZNTLZentalis Pharmaceuticals$67.43M3.99N/AN/A$2.99 per share1.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)EXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AMGNXMacroGenics-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)ZNTLZentalis Pharmaceuticals-$137.06M-$1.73N/AN/AN/AN/A-53.61%-40.67%8/5/2026 (Estimated)Latest EXOZ, MGNX, ZNTL, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A5/13/2026Q1 2026MGNXMacroGenics-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million5/12/2026Q1 2026ZNTLZentalis Pharmaceuticals-$0.49-$0.50-$0.01-$0.50N/AN/A5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/A3/26/2026Q4 2025ZNTLZentalis Pharmaceuticals-$0.41-$0.49-$0.08-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33EXOZeXoZymes0.031.321.32MGNXMacroGenicsN/A1.901.80ZNTLZentalis PharmaceuticalsN/A6.196.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%EXOZeXoZymesN/AMGNXMacroGenics96.89%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%EXOZeXoZymes72.41%MGNXMacroGenics13.60%ZNTLZentalis Pharmaceuticals3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableEXOZeXoZymes298.48 million2.34 millionN/AMGNXMacroGenics43063.56 million54.92 millionOptionableZNTLZentalis Pharmaceuticals16071.19 million68.48 millionOptionableEXOZ, MGNX, ZNTL, and AKBA HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial StrategyMay 27, 2026 | globenewswire.comZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum ...May 21, 2026 | finance.yahoo.comZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026May 21, 2026 | globenewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressMay 12, 2026 | globenewswire.comZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerMay 5, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerApril 21, 2026 | globenewswire.comZentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetApril 20, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...April 18, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026April 17, 2026 | globenewswire.comA Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection MilestoneApril 13, 2026 | finance.yahoo.comWhat's behind the surge in Zentalis stock?April 10, 2026 | msn.comWhat's Behind The Surge In Zentalis Stock?April 10, 2026 | benzinga.comZentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83April 10, 2026 | msn.comZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerApril 9, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesMarch 26, 2026 | globenewswire.comZentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026March 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, MGNX, ZNTL, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$0.94 +0.01 (+1.54%) Closing price 04:00 PM EasternExtended Trading$0.93 -0.01 (-1.03%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.eXoZymes NASDAQ:EXOZ$7.35 +0.25 (+3.52%) Closing price 04:00 PM EasternExtended Trading$7.44 +0.10 (+1.29%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.MacroGenics NASDAQ:MGNX$4.13 +0.17 (+4.29%) Closing price 04:00 PM EasternExtended Trading$4.13 0.00 (-0.02%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Zentalis Pharmaceuticals NASDAQ:ZNTL$3.78 +0.03 (+0.80%) Closing price 04:00 PM EasternExtended Trading$3.74 -0.04 (-1.16%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
